Robert Balfour
Amministratore Delegato presso Promatix, Inc.
Profilo
Robert Balfour is currently the Chief Executive Officer at Promatix, Inc. and an Investment Director at Alsa Management Services Ltd.
He holds a doctorate degree from Imperial College London and an undergraduate degree from Southampton Business School.
Posizioni attive di Robert Balfour
| Società | Posizione | Inizio |
|---|---|---|
Alsa Management Services Ltd
 Alsa Management Services Ltd Investment ManagersFinance Alsa Management Services Ltd (ALSA Ventures) is a venture capital firm founded in 2018. The firm is headquartered in London, United Kingdom. | Investitore di Private Equity | 01/07/2018 |
Promatix, Inc.
 Promatix, Inc. Data Processing ServicesTechnology Services Promatix, Inc. is based in London, UK. The British company takes a data-driven approach by utilizing a confluence of multi-omic datasets and proprietary algorithms. Promatix, Inc. is a company that was founded to accelerate the process of novel target and drug discovery for cancer patients. The company was founded in 2020, and Robert Balfour has been the CEO of the company since 2021. | Amministratore Delegato | 01/03/2021 |
Formazione di Robert Balfour
| Imperial College London | Doctorate Degree |
| Southampton Business School | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Alsa Management Services Ltd
Alsa Management Services Ltd Investment ManagersFinance Alsa Management Services Ltd (ALSA Ventures) is a venture capital firm founded in 2018. The firm is headquartered in London, United Kingdom. | Finance |
Promatix, Inc.
Promatix, Inc. Data Processing ServicesTechnology Services Promatix, Inc. is based in London, UK. The British company takes a data-driven approach by utilizing a confluence of multi-omic datasets and proprietary algorithms. Promatix, Inc. is a company that was founded to accelerate the process of novel target and drug discovery for cancer patients. The company was founded in 2020, and Robert Balfour has been the CEO of the company since 2021. | Technology Services |
- Borsa valori
- Insiders
- Robert Balfour
